Owkin
Collaborative research platform and unique AI drug development solutions that make precision medicine a reality.
- biotechnology
- horizon europe
- dt and ls
- core ai
- radar de l'innovation
- analytics
- generative ai
- oncology
- eit ecosystem
- genai applications
- verified unicorns and $1b exits
- observatoire deeptech
- drug development
- eit health
- biotech, medtech and e-health
- nif defense security and resilience
- ai drug discovery
- techbio
- tech for biotech and pharma
- physician support tools
- comparison
- digital pharma
- ai model layer
- techbio drug discovery
- privacy protection
- genai model maker
- privacy-enhancing technologies
- precision medicine
- medical research
- participations bpifrance
- nif health crisis preparedness
- clinical trials
- modeling
- radiology
- compbio
- nif biotech
- novel ai
- pathology
- gold track (eit health)
- gold track 2021 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
* | $80.0m Valuation: $1.0b | Series B | |
| Total Funding | 000k | ||
| EUR | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 229 % | 88 % | 40 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 10 % | 34 % | 9 % | 17 % |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Owkin is a pioneering company in the healthcare and biotechnology sector, specializing in AI-powered diagnostics and drug development. The company leverages advanced machine learning and biological insights to streamline and de-risk clinical trials, thereby accelerating the drug development process. Owkin serves a diverse clientele, including leading biopharma companies and top academic centers, by providing AI-driven solutions that integrate seamlessly into digital pathology workflows for accurate and timely diagnosis. The company operates in the global healthcare market, focusing on oncology and other critical disease areas. Owkin's business model revolves around partnerships and collaborations, offering bespoke AI models and multimodal patient data to enhance clinical trial recruitment and outcomes. Revenue is generated through strategic alliances, research collaborations, and the provision of AI diagnostics and data services.
Keywords: AI diagnostics, drug development, clinical trials, digital pathology, machine learning, oncology, biopharma, multimodal data, precision medicine, healthcare innovation.
